Get the Stockscreener App
15.59
4.24%
-0.69
After Hours:
15.70
0.11
+0.71%
Adma Biologics Inc stock is traded at $15.59, with a volume of 2.30M.
It is down -4.24% in the last 24 hours and down -13.05% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$16.28
Open:
$16.13
24h Volume:
2.30M
Relative Volume:
0.91
Market Cap:
$3.71B
Revenue:
$488.56M
Net Income/Loss:
$209.45M
P/E Ratio:
18.31
EPS:
0.8515
Net Cash Flow:
$40.61M
1W Performance:
-2.20%
1M Performance:
-13.05%
6M Performance:
-6.98%
1Y Performance:
-1.58%
1-Day Range:
$15.55
$16.14
1-Week Range:
$15.55
$16.65
52-Week Range:
$13.76
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
15.59 | 3.87B | 488.56M | 209.45M | 40.61M | 0.8515 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note - Nasdaq
Navellier & Associates Inc. Has $176,000 Stake in ADMA Biologics Inc $ADMA - MarketBeat
New York State Common Retirement Fund Decreases Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Principal Financial Group Inc. Cuts Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Renaissance Group LLC Has $7.57 Million Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
(ADMA) Risk Channels and Responsive Allocation - Stock Traders Daily
Assessing ADMA Biologics (ADMA) Valuation After Growing Analyst Optimism On Earnings And Plasma Therapy Pipeline - Yahoo Finance
Homestead Advisers Corp Has $2.91 Million Position in ADMA Biologics Inc $ADMA - MarketBeat
Is ADMA Biologics (ADMA) Pricing Reflect A Potential Gap To DCF And P/E Estimates - Yahoo Finance
ADMA Biologics (NASDAQ:ADMA) Seems To Use Debt Rather Sparingly - 富途牛牛
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Federated Hermes Inc. Reduces Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking A 48% Potential Upside - DirectorsTalk Interviews
Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc $ADMA Shares Bought by Thrivent Financial for Lutherans - MarketBeat
Is it worth investing in Adma Biologics (ADMA) based on Wall Street's bullish views? - MSN
Aug Movers: Does Assured Guaranty Ltd have strong EBITDA marginsJuly 2025 Gainers & Reliable Price Action Trade Plans - baoquankhu1.vn
Returns Recap: Is Celularity Inc Equity Warrant forming higher highs and higher lowsWeekly Market Outlook & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
ADMA Biologics Inc $ADMA Shares Sold by Lisanti Capital Growth LLC - MarketBeat
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? - Finviz
A Look At ADMA Biologics (ADMA) Valuation After Strong Analyst Support And Growing Interest In Its Therapies - Sahm
Insider Buy: Whats the beta of ADMA Biologics Inc stockDividend Hike & Low Risk Entry Point Guides - baoquankhu1.vn
Kornitzer Capital Management Inc. KS Acquires 312,115 Shares of ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Enters Oversold Territory (ADMA) - Nasdaq
Adma Biologics (ADMA) outpaces stock market gains: What you should know - MSN
ADMA Biologics Inc (ADMA) Stock Analysis: Unlocking A 53% Upside Potential - DirectorsTalk Interviews
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know - Nasdaq
(ADMA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Dow Update: Is ADMA Biologics Inc stock forming a cup and handleEarnings Recap Report & Weekly Return Optimization Alerts - baoquankhu1.vn
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
ADMA Biologics (ADMA) Is Down 5.0% After Expanding Multi-Year Revenue Guidance TargetsHas The Bull Case Changed? - Sahm
High Growth US Tech Stocks To Watch In January 2026 - Yahoo Finance
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Campbell & CO Investment Adviser LLC Purchases Shares of 64,535 ADMA Biologics Inc $ADMA - MarketBeat
What are ADMA Biologics Inc.’s growth leversJuly 2025 Trends & Low Drawdown Investment Ideas - bollywoodhelpline.com
Can ADMA Biologics Inc. stock sustain free cash flow growthLayoff News & Community Consensus Trade Alerts - bollywoodhelpline.com
Will ADMA Biologics Inc outperform small cap indexesJuly 2025 Opening Moves & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Retail Trends: Should I add ADMA Biologics Inc stock to my portfolio2025 Price Action Summary & Safe Capital Investment Plans - baoquankhu1.vn
ADMA Biologics reports preliminary 2025 results, ups 2026 outlook - MSN
Liquidity Mapping Around (ADMA) Price Events - Stock Traders Daily
ADMA Biologics, Inc. (ADMA): A Bull Case Theory - Finviz
Is Adma Biologics (ADMA) a buy as Wall Street analysts look optimistic? - MSN
ADMA Biologics: Business Update And My Price Target (NASDAQ:ADMA) - Seeking Alpha
Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? - sharewise.com
Breakout Zone: Whats the beta of ADMA Biologics Inc stock2025 Key Lessons & Safe Entry Momentum Stock Tips - baoquankhu1.vn
ADMA’s Upgraded Multi‑Year Revenue Targets Might Change The Case For Investing In ADMA Biologics (ADMA) - Sahm
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook - sharewise.com
How ADMA’s Multi‑Year Revenue Targets And Margin Push At ADMA Biologics (ADMA) Has Changed Its Investment Story - Yahoo Finance
ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.7%Should You Sell? - MarketBeat
A Look At ADMA Biologics (ADMA) Valuation After Raised Guidance And New Long Term Growth Targets - Yahoo Finance
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):